{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:38:21Z","timestamp":1781829501797,"version":"3.54.5"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,7,7]]},"DOI":"10.18632\/oncotarget.28470","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:05:57Z","timestamp":1688735157000},"page":"709-718","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series"],"prefix":"10.18632","volume":"14","author":[{"given":"Mark","family":"Chang","sequence":"first","affiliation":[{"name":"University Medical Center of Southern Nevada, Las Vegas, NV 89102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Samlowski","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA"},{"name":"Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA"},{"name":"Department of Internal Medicine, University of Nevada, Reno, NV 89557, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Meoz","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA"},{"name":"Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1708701","article-title":"Update on Keratinocyte Carcinomas","volume":"37","author":"Bichakjian","year":"2018","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jaad.2017.08.058","article-title":"Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors","volume":"7","author":"Schmults","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"6","author":"Schmults","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging","volume":"7","author":"Schmults","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women\u2019s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma","volume":"15","author":"Schmults","year":"2019","journal-title":"JAMA Dermatol"},{"key":"6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjd.16892","article-title":"The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K","volume":"17","author":"Slater","year":"2018","journal-title":"Br J Dermatol"},{"key":"7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/DSS.0000000000001038","article-title":"Comparison of the American Joint Committee on Cancer Seventh Edition and Brigham and Women\u2019s Hospital Cutaneous Squamous Cell Carcinoma Tumor Staging in Immunosuppressed Patients","volume":"4","author":"Nguyen","year":"2017","journal-title":"Dermatol Surg"},{"key":"8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2012.48.5326","article-title":"Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women\u2019s Hospital tumor staging for cutaneous squamous cell carcinoma","volume":"3","author":"Schmults","year":"2014","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamadermatol.2013.6675","article-title":"Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system","volume":"15","author":"Baum","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1634\/theoncologist.2009-0210","article-title":"Treatment of unresectable and metastatic cutaneous squamous cell carcinoma","volume":"1","author":"Morgan","year":"2010","journal-title":"Oncologist"},{"key":"11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/hed.23684","article-title":"Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck","volume":"3","author":"Rao","year":"2015","journal-title":"Head Neck"},{"key":"12","first-page":"1205","article-title":"Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin","volume":"2","author":"Avril","year":"2005","journal-title":"Anticancer Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"2","author":"Duval-Modeste","year":"2011","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"2","author":"Porceddu","year":"2014","journal-title":"Ann Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study","volume":"1","author":"Brunet-Possenti","year":"2020","journal-title":"Oncotarget"},{"key":"16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/09546634.2012.751481","article-title":"Efficacy of cetuximab in the treatment of squamous cell carcinoma","volume":"2","author":"Dreno","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"17","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Ulrich","year":"2020","journal-title":"J Immunother Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"3","author":"Saiag","year":"2020","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"37","author":"Dunn","year":"2018","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"8","author":"King","year":"1984","journal-title":"J Invest Dermatol"},{"key":"21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-0560.1992.tb01561.x","article-title":"Abnormal expression of epidermal growth factor receptor in cutaneous epithelial tumours","volume":"1","author":"MacDonald","year":"1992","journal-title":"J Cutan Pathol"},{"key":"22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s0959-8049(00)00364-6","article-title":"Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer","volume":"3","author":"Peter","year":"2001","journal-title":"Eur J Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000051637","article-title":"Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin","volume":"20","author":"Sasaki","year":"2001","journal-title":"Dermatology"},{"key":"24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/1523-1747.ep12340759","article-title":"EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation","volume":"10","author":"Pittelkow","year":"1997","journal-title":"J Invest Dermatol"},{"key":"25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/s0014-4827(02)00043-5","article-title":"UVB-induced apoptosis in normal human keratinocytes: role of the erbB receptor family","volume":"28","author":"Spandau","year":"2003","journal-title":"Exp Cell Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"874571","DOI":"10.1155\/2011\/874571","article-title":"Inhibition of Epidermal Growth Factor Receptor and PI3K\/Akt Signaling Suppresses Cell Proliferation and Survival through Regulation of Stat3 Activation in Human Cutaneous Squamous Cell Carcinoma","volume":"201","author":"Nishigori","year":"2011","journal-title":"J Skin Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1034\/j.1600-0625.2003.00101.x","article-title":"Involvement of EGF receptor activation in the induction of cyclooxygenase-2 in HaCaT keratinocytes after UVB","volume":"1","author":"Ueda","year":"2003","journal-title":"Exp Dermatol"},{"key":"28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/era.11.20","article-title":"Cetuximab in the treatment of squamous cell carcinoma of the head and neck","volume":"1","author":"Vermorken","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"29","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"5","author":"Harari","year":"1999","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"35","author":"Baselga","year":"2006","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"1","author":"Ang","year":"2010","journal-title":"Lancet Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial","volume":"12","author":"Glisson","year":"2018","journal-title":"Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/1754-9485.12842","article-title":"Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma","volume":"6","author":"Walker","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"284582","DOI":"10.1155\/2014\/284582","article-title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy","volume":"201","author":"Barker","year":"2014","journal-title":"J Skin Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/COC.0000000000000228","article-title":"Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"4","author":"Lien","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"36","first-page":"D5962","article-title":"[The mortality in Amsterdam from 1554 to 2021]","volume":"16","author":"Kaplan","year":"2021","journal-title":"Ned Tijdschr Geneeskd"},{"key":"37","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0","author":"U.S. Department of Health and Human Services","year":"2010","journal-title":"NIH, National Cancer Institute"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:06:03Z","timestamp":1688735163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7,7]]}},"alternative-id":["28470"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28470","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}